

Consultation on the renewal of Federal Tobacco Control Strategy

<https://policybase.cma.ca/en/permalink/policy13804>

Policy Type: Response to consultation
 Date: 2017-04-05
 Topics: Health care and patient safety
 Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs



Documents



BR2017-13.pdf

 Read PDF

 Download PDF



CMA response to patented medicines regulations consultations

<https://policybase.cma.ca/en/permalink/policy13690>

Policy Type: Response to consultation
Date: 2017-06-28
Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs

Documents

BR2017-08.pdf

 Read PDF

 Download PDF



Excise duty framework for cannabis products

<https://policybase.cma.ca/en/permalink/policy13799>

Policy Type: Response to consultation

Date: 2017-12-07

Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs

Documents

BR2018-06.pdf

 Read PDF

 Download PDF

The document thumbnail shows the same blue header as the first image, with the title 'CMA Submission: Excise Duty Framework for Cannabis Products' and the subtitle 'Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products'. The date 'December 7, 2017' and the CMA and 150 logos are also present. Below the thumbnail, the filename 'BR2018-06.pdf' is displayed. At the bottom of the document preview area, there are two buttons: 'Read PDF' with a document icon and 'Download PDF' with a download icon.

Non-prescription availability of low-dose codeine products

<https://policybase.cma.ca/en/permalink/policy13734>

Policy Type: Response to consultation

Date: 2017-11-7

Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs



Documents



Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations in the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescription only

November 7, 2017



BR2018-04.pdf

 Read PDF

 Download PDF